Key result
Troponin rises in ~40% of adult SVT cases, mostly reflecting benign demand ischemia without prognostic value.
Why the study?
Troponin elevation is common in supraventricular tachycardia, but its clinical significance remains uncertain and may trigger unnecessary downstream testing.
Does troponin elevation predict adverse cardiovascular outcomes in adult patients with paroxysmal supraventricular tachycardia?
Does troponin elevation predict adverse cardiovascular outcomes in adult patients with paroxysmal supraventricular tachycardia?
Troponin elevation in supraventricular tachycardia is common and typically benign, indicating that routine testing should be avoided in favor of a selective approach based on ischemic symptoms or high-risk features.
Answers are grounded in this paper and cite their sources.
May warrant selective troponin testing in SVT to limit unnecessary admissions; leaves open optimal risk-stratification strategies.
Supraventricular tachycardia (SVT) is a frequent cause of emergency presentations. Troponin elevation is common, but its clinical significance remains uncertain and may trigger unnecessary downstream testing. In this mini-review, we aimed to review the prevalence, mechanisms, prognostic relevance, and management of troponin elevation in adult paroxysmal SVT. A narrative review was conducted using PubMed and EMBASE (2000-2025) with MeSH terms related to SVT and troponin. Eligible studies included original research or registry analyses in adults with paroxysmal SVT. Pediatric and atrial fibrillation/flutter cohorts were excluded. Additional data were obtained from reference lists and expert commentaries. Troponin elevation occurs in approximately 30%-50% of adult SVT cases, primarily reflecting a tachycardia-induced supply-demand imbalance or myocardial stretch, rather than plaque rupture. Short-term registry data suggest potential prognostic associations, but long-term outcomes remain inconsistent and are largely determined by comorbidities and underlying coronary artery disease. Troponin-driven management often leads to increased admissions, consultations, and additional testing without a demonstrable benefit. Troponin elevation in SVT is frequent but usually benign. Routine measurement in all patients is not justified. A selective, risk-based approach - focused on ischemic symptoms, electrocardiogram changes, or high-risk clinical features - offers more appropriate, efficient, and patient-centered care.
No takes yet. Share an insight, caveat, or question.
Özlek et al. (2025) conducted a review in Paroxysmal supraventricular tachycardia. Troponin elevation vs. Normal troponin levels was evaluated. Troponin elevation occurs in 30% to 50% of adult supraventricular tachycardia cases, typically reflecting benign supply-demand imbalance rather than acute coronary syndrome, and has inconsistent prognostic value.
Synapse has enriched 10 related papers. Consider them for comparative context: